Pathos AI partners with Bristol Myers Squibb and Tempus to launch AI‑driven neuroscience program
+1 new source since this summary was written
Pathos AI announced collaborations with Bristol Myers Squibb (BMS) and Tempus AI to create a large, de‑identified neurological patient dataset and apply its Foundry AI platform to it. BMS is leading Pathos’s Series E financing, providing $237 million and securing three‑year exclusive use of Foundry for its neuroscience projects plus broader non‑exclusive access. Tempus will construct the dataset and license it to Pathos for $55 million over five years.
Why it matters
BMS expects the AI tools to speed insight into disease progression and improve clinical‑trial design for its Alzheimer’s and other brain‑disorder programs. Tempus gains a $55 million revenue stream from the data license and deepens its partnership with a fast‑growing AI company.
Key facts
- 1Pathos AI will receive a five‑year data license from Tempus valued at $55 million. stocktitan.net
- 2Tempus will assemble a de‑identified longitudinal dataset drawn from hundreds of thousands of neurological patients. finance.yahoo.com
- 3Bristol Myers Squibb is leading Pathos AI’s Series E financing round, contributing $237 million and valuing the company at about $3 billion. finance.yahoo.com
- 4BMS obtains three‑year exclusive rights to use Pathos Foundry for its neuroscience development programs. investing.com
- 5BMS also receives non‑exclusive strategic access to Pathos Foundry across its broader research and development portfolio. investing.com
Summary written by AlphAI AI Desk from 4 of 5 sources. Not investment advice. Figures are as stated by the linked sources.